Researchers at the University of California San Diego School of Medicine, in collaboration with the Prevencasa free clinic in Tijuana, Mexico, have confirmed the presence of xylazine in the illicit drug supply at the U.S.–Mexico border. While xylazine remains less common in the Western U.S., border cities serve as key trafficking hubs and may have higher rates of emerging substances.